ESALY News and Press, Eisai Co. Ltd. ADR From 05/26/22

Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 TOKYO, May 27, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology...

Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS TOKYO, May 27, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has...

Eisai Co., Ltd. (ESALF) Q4 2022 Earnings Conference Call May 13, 2022 3:30 AM ET Company Participants Haruo Naito - CEO Ivan Cheung - Senior VP & President of Neurology Business Group Teruyuki Masaka - VP & Chief Planning Officer Takashi Owa - Senior VP, President & Chief Discover...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALY) (OTCPK:ESALF) completed a rolling submission to the U.S. Food and Drug Administration (FDA) of their medicine lecanemab to treat Alzheimer’s disease (AD). The companies said the biologics license application (BLA) was submitte...

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway TOKYO and CAMBRIDGE, Mass., May 10, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today th...

Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan TOKYO, May 10, 2022 - (JCN Newswire) - Eisai Co., Ltd. today announced that it has in...

EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY PR Newswire TOKYO and CAMBRIDGE, Mass. , May 9, 2022 /PRNewswire/ -- Eisai Co., Ltd....

The adj. earnings per share of Biogen (NASDAQ:BIIB) fell short of Street forecasts by as much as $0.74 in1Q 2022 as the as the company said it recognized $0.76 charge to reflect write offs related to the Alzheimer’s drug Aduhelm which was approved by the FDA last year. While the FDA si...

At this point, Eli Lilly's donanemab performs only a tick better than Biogen's aducanumab/Aduhelm for Alzheimer's disease. The FDA may grant accelerated approval to donanemab as it did for aducanumab based on the removal of amyloid plaques as a surrogate biomarker. Medicare, thoug...

Efforts to manipulate growth factors including those being undertaken by Athira and Synaptogenix are unlikely to be successful because the pathway through which growth factors work is inhibited by nitration. Anti-amyloid treatments such as those being undertaken by Biogen and Eisai, E...